Obinutuzumab
Carcinoma, Non-Small-Cell Lung
NeoTX Therapeutics Ltd.monoclonal_antibodyPhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 65/ 100
Competitive context
113 Active assets in the Carcinoma, Non-Small-Cell Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab Novartis Pharmaceuticals | Phase 3 | BB |
Lazertinib Janssen Research & Development, LLC | Phase 3 | BB |
DEXAMETHASONE Rigshospitalet, Denmark | Phase 4 | BB |
Lorlatinib Chugai Pharmaceutical | Phase 4 | BB |
Vinorelbine Guangzhou Institute of Respiratory Disease | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Obinutuzumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →